Showing 8,041 - 8,060 results of 188,786 for search '(( 1 a decrease ) OR ( 50 ((((a decrease) OR (we decrease))) OR (nn decrease)) ))', query time: 2.52s Refine Results
  1. 8041

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    “…In search for selective modulators of the D<sub>1</sub> receptor, the screening of a chemical library and subsequent medicinal chemistry program around an identified hit resulted in new synthetic compound <b>26</b> [UCM-1306, 2-(fluoromethoxy)-4′-(<i>S</i>-methanesulfonimidoyl)-1,1′-biphenyl] that increases the dopamine maximal effect in a dose-dependent manner in human and mouse D<sub>1</sub> receptors, is inactive in the absence of dopamine, modulates dopamine affinity for the receptor, exhibits subtype selectivity, and displays low binding competition with orthosteric ligands. …”
  2. 8042

    2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for... by Javier García-Cárceles (2073898)

    Published 2022
    “…In search for selective modulators of the D<sub>1</sub> receptor, the screening of a chemical library and subsequent medicinal chemistry program around an identified hit resulted in new synthetic compound <b>26</b> [UCM-1306, 2-(fluoromethoxy)-4′-(<i>S</i>-methanesulfonimidoyl)-1,1′-biphenyl] that increases the dopamine maximal effect in a dose-dependent manner in human and mouse D<sub>1</sub> receptors, is inactive in the absence of dopamine, modulates dopamine affinity for the receptor, exhibits subtype selectivity, and displays low binding competition with orthosteric ligands. …”
  3. 8043
  4. 8044
  5. 8045
  6. 8046
  7. 8047
  8. 8048

    Fig 3 - by Hyun-Jun Kim (1561153)

    Published 2021
    “…E) Densitometry analysis of atrogin-1, MuRF-1, mTOR and phosphorylated mTOR expression. ** = <i>p</i><0.01 indicates significantly decreased or increased expression compared to the untreated control (n = 4).…”
  9. 8049
  10. 8050
  11. 8051

    Poly(I:C) at a low dose inhibits <i>A</i>. <i>flavus</i> induced AHR and acute eosinophilia. by Li She (2204779)

    Published 2020
    “…Administration of Poly(I:C) decreased the percentage and number of eosinophils in lungs after exposure to <i>A</i>. …”
  12. 8052

    Fig 6 - by Hyun-Jun Kim (1561153)

    Published 2021
    “…The IC<sub>50</sub> 3.49 μM, 2.94 μM, and 3.07 μM, respectively. ** = <i>p</i><0.01 and **** = <i>p</i><0.0001 indicate significantly decreased viability compared to the untreated control. …”
  13. 8053

    Fig 2 - by Hyun-Jun Kim (1561153)

    Published 2021
    “…Myoblasts were differentiated for 72 h and treated with 10 μM Dex, or 10 μM Dex plus 300 nM or 600 nM Ni or 50 ng/ml bovine insulin for 24 h. B) Average diameter of C2C12 myotubes treated with Dex or Dex+Ni. *** = <i>p</i><0.001 indicate significantly decreased compared to the untreated control. ### = <i>p</i><0.001 to indicate significantly increased myotube diameter compared to Dex treated myotubes. …”
  14. 8054
  15. 8055
  16. 8056
  17. 8057

    Body weight and ovarian characteristics following CR in POLG<sup>D257A/257A</sup> female mice. by Christine Faraci (5778434)

    Published 2018
    “…<p><b>A.</b> Body weight was decreased following the onset of CR. …”
  18. 8058

    Mendelian randomization results with COVID-19. by Alish B. Palmos (5857379)

    Published 2022
    “…Using genetic instruments and under the assumptions of Mendelian randomization, the top section shows results consistent with six blood markers being significantly causally associated with an increased risk of hospitalization as a result of COVID-19 and the nine blood markers causally associated with a decreased risk of hospitalization, as well as one protein showing a decrease in risk of hospitalization. …”
  19. 8059
  20. 8060